Clinical trial
A Phase I, Multicenter, Open-Label, Single-Arm, Dose-Escalation, Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 in Adults With B-Cell Non-Hodgkin's Lymphoma Not Eligible for Curative Therapy
NCT00538096 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multicenter, Open-Label, Single-Arm, Dose-Escalation, Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 in Adults With B-Cell Non-Hodgkin's Lymphoma Not Eligible for Curative Therapy
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- September 30, 2007
- Completion date
- May 31, 2010
- Enrollment
- 18 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.